Retatrutide - Top-Line Results from TRIUMPH 4
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
Retatrutide - Top-Line Results from TRIUMPH 4
-
Narrado por:
-
De:
In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.
Highlights:
- Up to 28.7% weight loss (~71 lbs) over 68 weeks
- 75% reduction in knee pain and major improvements in physical function
- Cardiometabolic benefits: lower triglycerides, non-HDL cholesterol, hsCRP, and blood pressure
We also cover
- Common side effects and safety signals
- Perceived excessive weight loss — and what this means for clinical practice in a new era of powerful medications
- A reality check on Canadian availability (likely 3+ years away)
- A strong warning about illegal online sales and the risks of buying unregulated products
A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.
Todavía no hay opiniones